Bio-Techne to be acquired by Merck KGaA for $73.00 per share in all-cash deal

BIO-TECHNE Corp

Merck KGaA to acquire Bio-Techne (TECH) for $73.00 per share in cash.
Termination fees: Company pays $230.5M for superior proposal; Parent pays $576.1M for antitrust failure.
Retention bonuses: CEO Kelderman $2.12M, CFO Hippel $1.54M, plus Geist $1.16M, Bohnen $0.97M, Crouse $0.91M.
Closing requires shareholder approval, HSR and antitrust clearances; outside date Mar 25, 2027, extendable.
Board unanimously recommends the merger; subject to no-shop and fiduciary-out provisions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.